SAB Biotherapeutics: Director Departs, New Director Elected
Ticker: SABSW · Form: 8-K · Filed: May 31, 2024 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $303,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, management
TL;DR
SAB Biotherapeutics swapped a director for a new one, effective May 26th.
AI Summary
SAB Biotherapeutics, Inc. announced on May 26, 2024, the departure of Director Dr. Steven M. Deitcher and the election of Dr. David L. R. Gray as a new director. The company also reported on compensatory arrangements for its officers. This filing follows SAB Biotherapeutics' previous name change from Big Cypress Acquisition Corp. on November 20, 2020.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board changes and compensatory arrangements, with no immediate financial distress or significant operational shifts indicated.
Key Numbers
- 20240526 — Report Date (Date of earliest event reported)
- 20201120 — Name Change Date (Date of former company name change)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Dr. Steven M. Deitcher (person) — Departing Director
- Dr. David L. R. Gray (person) — Newly Elected Director
- Big Cypress Acquisition Corp. (company) — Former Company Name
FAQ
Who has been appointed as a new director to the board of SAB Biotherapeutics, Inc.?
Dr. David L. R. Gray has been elected as a new director.
Who has departed from the board of directors of SAB Biotherapeutics, Inc.?
Dr. Steven M. Deitcher has departed from the board of directors.
What is the effective date of the reported board changes?
The earliest event reported is dated May 26, 2024.
What was SAB Biotherapeutics, Inc. previously known as?
SAB Biotherapeutics, Inc. was formerly known as Big Cypress Acquisition Corp.
What other information is disclosed in this 8-K filing besides director changes?
The filing also covers the election of certain officers and compensatory arrangements for certain officers.
Filing Stats: 1,087 words · 4 min read · ~4 pages · Grade level 10.4 · Accepted 2024-05-30 18:49:48
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
- $303,000 — ovides for (i) an annual base salary of $303,000; (ii) eligibility to participate in the
Filing Documents
- sabs-20240526.htm (8-K) — 46KB
- sabs-ex10_1.htm (EX-10.1) — 23KB
- sabs-ex99_1.htm (EX-99.1) — 13KB
- img83562661_0.jpg (GRAPHIC) — 40KB
- 0000950170-24-066856.txt ( ) — 295KB
- sabs-20240526.xsd (EX-101.SCH) — 46KB
- sabs-20240526_htm.xml (XML) — 6KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 30, 2024, the Company issued a press release, a copy of which is filed herewith as Exhibit 99.1, announcing the appointment of Mr. Conley. The information set forth in this Item 7.01 and in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibits. Exhibit Number Description 10.1 Employment Agreement between SAB Biotherapeutics, Inc. and Mark Conley dated November 6, 2023 99.1 Press Release of the Company, dated May 30, 2024 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: May 30, 2024 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer